How long can one live after evantumumab is used to treat lung cancer?

Evantumumab is a drug targeting lung cancer. Studies have shown that evantumumab can significantly extend the survival of lung cancer patients and reduce the activity of lung cancer cells that overexpress EGFR and MET receptors. However, the survival time of lung cancer patients is affected by many factors, including the severity of the disease, the patient's overall health, and the type and stage of the lung cancer. Therefore, it is impossible to accurately predict how long each patient will live with .

Effectiveness of evantumumab in the treatment of lung cancer

CHRYSALIS is an open-label, dose escalation and dose expansion phase I study in patients with epidermal growth factor receptor exon 20ins NSCLC. The primary endpoints were dose-limiting toxicities and overall response rate. The trial reports results from a study of patients with EGFR Exon20ins NSCLC after platinum therapy treated with the recommended phase II dose of 1,050 mg evantumumab (1,400 mg, ≥ 80 kg) once weekly for the first 4 weeks, then every 2 weeks starting at week 5.

Results

The median age of the efficacy population (n = 81) was 62 years old (42-84 years old); 40 patients (49%) were Asian, and the median number of previous treatments was 2 times (1-7 times). The overall response rate was 40%, including 3 complete responses, and the median duration of response was 11.1 months. The median progression-free survival was 8.3 months.

Conclusion

Evantumumab, through its novel mechanism of action, produced a robust and durable response with a tolerable safety profile in patients with epidermal growth factor receptor exon 20ins mutations after progression on platinum-based chemotherapy.

Pharmacodynamics of evantumumab

Evantumumab is an antibody directed against the EGF and MET receptors and is indicated for the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations. The duration of action of evantumumab is long, as activity is detectable up to 8 weeks after treatment. 1Patients should be informed of the risks of infusion-related reactions, interstitial lung disease and pneumonitis, skin reactions, ocular toxicity, and paronychia. Patients who are pregnant or breastfeeding should not take evantumumab.

For more information on the precautions for the use of evantuzumab, please click: ? This article has a detailed introduction.

How to take evantumumab

Evantumumab injection is a solution (liquid) that is slowly injected into a vein by a doctor or nurse at a medical facility or infusion center. Initially, it is usually administered once daily for 2 days. After the first 2 doses, doses are usually given every two weeks for as long as you continue treatment. The length of treatment depends on how your body responds to the medication and the side effects you experience.

A doctor or nurse will watch you closely during and after your evantumumab infusion to make sure you do not have a serious reaction to the drug. You may be given other medicines to help prevent reactions to evantumumab. Tell your doctor or nurse right away if you develop any of the following symptoms during the infusion: nausea, shortness of breath, fever, chills, flushing, chest pain, dizziness, nausea, or vomiting.

If a patient experiences certain side effects, your doctor may need to slow down your infusion or interrupt or stop treatment. Talk with your doctor about how you are feeling during and after treatment.

Recommended hot articles:

References

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2. PMID: 34339292; PMCID: PMC8791812.